Impact of fingolimod on CD4+T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients

Kurtuncu, Murat; Yilmaz, Vuslat; Akcay, Halil; Turkoglu, Recai; Altunrende, Burcu; Cinar, Suzan; Ulusoy, Canan; Gunduz, Tuncay; Icoz, Sema; Kasap, Mithat; Caliskan, Zeynep; Otunc, Gokturk; Eraksoy, Mefküre; Tuzun, Erdem

doi:10.1016/j.jneuroim.2019.577065

Impact of fingolimod on CD4+T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients

Atıf İçin Kopyala

Kurtuncu M., Yilmaz V., Akcay H. I., Turkoglu R., Altunrende B., Cinar S., ...Daha Fazla

JOURNAL OF NEUROIMMUNOLOGY, cilt.337, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 337
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.jneuroim.2019.577065
Dergi Adı: JOURNAL OF NEUROIMMUNOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Fingolimod, Sphingosine-1-phosphate receptor, Cytokine, Chemokine, T cell, REGULATORY T-CELLS, ORAL FINGOLIMOD, INTERFERON, EXPRESSION, TH17
İstanbul Üniversitesi Adresli: Evet

Özet

Fingolimod inhibits the egress of lymphocytes from lymphatic tissues and also directly affects their functions by modulation of the sphingosine-1 -phosphate receptor 1 (S1P1). Our aim was to evaluate the impact of fingolimod on diverse CD4+ T cell subsets, and cytokines.